145 results
8-K
ZVRA
Zevra Therapeutics Inc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
of $5.6 million as of September 30, 2022.
The errors and corrective adjustments described in this Form 8-K are non-cash in nature, and do not impact
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
.
The errors and corrective adjustments identified by the Company are non-cash in nature; and they do not impact results of operations or key metrics used
8-K
EX-3.1
ZVRA
Zevra Therapeutics Inc
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
limitation, court costs, attorneys’ fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind
424B5
0hgdaqyefe1sn8d
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
EX-10.1
3ryrg9u8 nyshsoe
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.2
sdoiru9
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
oucgz27ojetu rz1n3
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
eimbyuzbvh wxmaxoz
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
ked0wn
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
49unnyxzq
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
w4lmia82
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-10.3
hu3gk vio1brkn9ape
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-2.1
27e9m2jazn
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
ka0240e73vb7002woqr
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.2
3occvn
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.5
vjd2iz4 d27ap
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.4
6hy z59ce
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am